Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available…”In the company’s words, NCT05322148 on ClinicalTrials.gov
- Tested for
- Dry Eye
- Main trialPhase 3
- “The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye”In the company’s words, NCT05322148 on ClinicalTrials.gov
Other drugs for Dry Eye
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 17 Nov 2022 | Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026